BMY logo

BRISTOL-MYERS SQUIBB CO

BMYNYSE
πŸ† #113 by market capEarnings Oct 29🧬Biotech
$63.35β–Ό $0.53 (βˆ’0.83%)
Live
πŸ””
Track BMY
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 0.8%
7dβ–² 1.8%
14dβ–Ό 0.6%
30dβ–Ό 4.9%
ytdβ–² 17.4%
1yβ–² 43.6%
🏦Market Cap
$129.41B
Mid Cap
πŸ“ˆRevenue Growth (YoY)
-0.2%
Declining
πŸ“ŠGross Margin
70.2%
High
πŸ’΅FCF Margin
23.3%
Strong
βš–οΈP/S Ratio
2.7x
Cheap
Otter Score
52
Weak

Trading Snapshot

Day Range
$62.43 – $63.62
52-Week Range
$42.52 – $68.64
Volume
$6.25B
Avg Volume
$5.17B
Shares Outstanding
2.04B
Next Earnings
Nov 21, 2026

Fundamentals Snapshot

Annual Revenue
$48.20B
Last Q Revenue
$12.97B
P/E Ratio
14.1
P/S Ratio
2.7x
EPS (TTM)
$4.55
Dividend Yield
3.93%
Dilution (1yr)
+0.2%

Why Investors Own BMY

  • βœ“High-growth profile β€” revenue up +2.6% YoY with expanding Biotech exposure.
  • βœ“Healthy economics β€” 37% gross margin and 17% free-cash-flow margin.
  • βœ“Deep pipeline with potential catalysts and durable IP.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

BMY logo

BRISTOL-MYERS SQUIBB CO

BMY
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$48.2Bβ–Ό βˆ’0.2% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
71.1%β–² +25.2% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$13.7Bβ–² +42.1% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$12.8Bβ–Ό βˆ’7.9% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
2.04Bβ–² +0.2% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$36.9Bβ–² +$3.9B YoY
StockOtter Β· stockotter.space

About BRISTOL-MYERS SQUIBB CO

Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Weak
52/100

Analyst Price Target

β“˜
Average Target
$65.50
β–² +3.4% Upside
High Target$76.16
Low Target$54.27
Based on 18 analysts

Latest News & Updates